- Home
- HEPA vs AEON Comparison
HEPA vs AEON Comparison
Compare HEPA & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPA
- AEON
- Stock Information
- Founded
- HEPA 2013
- AEON N/A
- Country
- HEPA United States
- AEON United States
- Employees
- HEPA N/A
- AEON N/A
- Industry
- HEPA Biotechnology: Pharmaceutical Preparations
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- HEPA Health Care
- AEON Health Care
- Exchange
- HEPA Nasdaq
- AEON Nasdaq
- Market Cap
- HEPA 863.9K
- AEON 5.9M
- IPO Year
- HEPA N/A
- AEON N/A
- Fundamental
- Price
- HEPA $0.48
- AEON $0.54
- Analyst Decision
- HEPA
- AEON Strong Buy
- Analyst Count
- HEPA 0
- AEON 1
- Target Price
- HEPA N/A
- AEON $360.00
- AVG Volume (30 Days)
- HEPA 5.3M
- AEON 7.6M
- Earning Date
- HEPA 05-20-2025
- AEON 03-24-2025
- Dividend Yield
- HEPA N/A
- AEON N/A
- EPS Growth
- HEPA N/A
- AEON N/A
- EPS
- HEPA N/A
- AEON 72.93
- Revenue
- HEPA N/A
- AEON N/A
- Revenue This Year
- HEPA N/A
- AEON N/A
- Revenue Next Year
- HEPA N/A
- AEON N/A
- P/E Ratio
- HEPA N/A
- AEON $0.01
- Revenue Growth
- HEPA N/A
- AEON N/A
- 52 Week Low
- HEPA $0.40
- AEON $0.40
- 52 Week High
- HEPA $145.00
- AEON $626.40
- Technical
- Relative Strength Index (RSI)
- HEPA 20.60
- AEON 24.27
- Support Level
- HEPA $0.40
- AEON $0.61
- Resistance Level
- HEPA $0.99
- AEON $0.61
- Average True Range (ATR)
- HEPA 0.18
- AEON 0.09
- MACD
- HEPA 0.32
- AEON 0.45
- Stochastic Oscillator
- HEPA 7.80
- AEON 9.91
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.